These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 16322248)

  • 1. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
    Isakoff SJ; Engelman JA; Irie HY; Luo J; Brachmann SM; Pearline RV; Cantley LC; Brugge JS
    Cancer Res; 2005 Dec; 65(23):10992-1000. PubMed ID: 16322248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
    Zhang H; Liu G; Dziubinski M; Yang Z; Ethier SP; Wu G
    Breast Cancer Res Treat; 2008 Nov; 112(2):217-27. PubMed ID: 18074223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.
    Wang GM; Wong HY; Konishi H; Blair BG; Abukhdeir AM; Gustin JP; Rosen DM; Denmeade SR; Rasheed Z; Matsui W; Garay JP; Mohseni M; Higgins MJ; Cidado J; Jelovac D; Croessmann S; Cochran RL; Karnan S; Konishi Y; Ota A; Hosokawa Y; Argani P; Lauring J; Park BH
    Cancer Res; 2013 Jun; 73(11):3248-61. PubMed ID: 23580570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
    Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
    Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
    Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
    Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
    Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
    Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating breast cancer by PIK3CA mutation.
    Miller TW
    Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
    Renner O; Blanco-Aparicio C; Grassow M; Cañamero M; Leal JF; Carnero A
    Cancer Res; 2008 Dec; 68(23):9643-53. PubMed ID: 19047141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The butterfly effect in cancer: a single base mutation can remodel the cell.
    Hart JR; Zhang Y; Liao L; Ueno L; Du L; Jonkers M; Yates JR; Vogt PK
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1131-6. PubMed ID: 25583473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
    Koren S; Bentires-Alj M
    FEBS J; 2013 Jun; 280(12):2758-65. PubMed ID: 23384338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.
    Dirican E; Akkiprik M; Özer A
    Tumour Biol; 2016 Jun; 37(6):7033-45. PubMed ID: 26921096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
    Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
    Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.